Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Concanavalin A (ConA) is a well-characterized legume lectin derived from the jack bean, Canavalia ensiformis, belonging to the carbohydrate-binding protein family (UniProt: P02866). It is widely utilized in biological research due to its high affinity for alpha-D-mannosyl and alpha-D-glucosyl residues, which allows it to bind and cross-link various cell surface glycoproteins (Wikipedia). ConA is primarily recognized for its role as a potent T-cell mitogen, frequently used to stimulate lymphocyte proliferation and study immune signaling cascades in vitro. In pharmacology, it is the standard agent used to induce experimental autoimmune hepatitis in murine models, providing a platform to investigate T-cell-mediated liver injury and the role of inflammatory cytokines like TNF-alpha (NIH). While research has explored its potential anti-tumor effects through the induction of apoptosis and autophagy in cancer cells, its clinical application is severely limited by its high systemic toxicity and strong immunogenic profile. Its structural properties as a homotetramer at neutral pH make it a robust tool for glycoproteomics and the purification of glycosylated molecules (PubMed).
Concanavalin A acts by specifically binding to alpha-D-mannosyl and alpha-D-glucosyl residues on cell surface glycoproteins, leading to the cross-linking of surface receptors (such as the T-cell receptor) and the subsequent activation of intracellular signaling pathways that drive mitogenesis or programmed cell death (PubMed).
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Concanavalin A (ConA).